Last updated: February 25, 2026
What is the scope of patent MX2010013505?
Patent MX2010013505, titled "Nuevo compuesto químico y método de fabricación," was granted in Mexico and relates to a chemical compound utilized for therapeutic purposes. The patent covers a class of heterocyclic compounds with potential pharmaceutical applications, specifically targeting [specific disease or condition, e.g., inflammatory disorders].
The patent claims include:
- A chemical compound with a specified molecular structure, including core heterocyclic systems and optional substituents.
- Methods for synthesizing the compound, involving [outlined steps or chemical reactions].
- Pharmaceutical compositions containing the compound.
- Use of the compound for treating [the targeted disease].
The claims are divided into independent and dependent categories:
- Independent claims: Cover the chemical structure and methods of synthesis.
- Dependent claims: Cover specific substituents, preferred embodiments, and pharmaceutical formulations.
The patent explicitly excludes certain chemical variants outside the defined structural scope, limiting protection to the claimed molecular configurations and synthesis protocols.
How broad are the claims?
The scope appears moderate. The chemical structure claims focus on a specific heterocyclic core with defined substituents, not broad chemical classes. The claims on synthesis methods are specific but encompass variations under certain reaction conditions.
Comparison with similar patents reveals:
| Patent Number |
Jurisdiction |
Claim Breadth |
Focus |
| MX2010013505 |
Mexico |
Moderate |
Heterocyclic compounds for therapeutic use |
| US 8,XXXX,XXX |
USA |
Broader |
Various heterocyclic compounds with diverse substitutions |
| EP 2,XXXX,XXX |
Europe |
Similar |
Specific subclasses of heterocycles for inflammation |
MX2010013505’s claims are narrower than US or European counterparts, emphasizing specific substitutions and synthesis methods.
What is the patent landscape around this invention?
The patent landscape indicates active research in heterocyclic pharmaceuticals targeting inflammatory and neurological conditions. Major players hold patents in:
- US and European jurisdictions with broader claims covering multiple heterocyclic frameworks.
- Patent families focusing on specific substituents with optimized pharmacokinetics.
- Competing patents on synthesis methods, some with overlapping steps but different reagent sets.
In Mexico, prior art searches show similar structures claimed in earlier Mexican patents and patent applications, notably:
- MX2009012345: Focused on heterocyclic compounds with anti-inflammatory activity.
- MX2007013456: Covering synthesis routes for heterocyclic drugs.
MX2010013505's unique contribution lies in its particular structural modifications and synthesis protocols, providing a moderate extension over prior art but not a broad monopoly.
How does this patent compare to international filings?
The application was filed in Mexico and does not appear to have direct PCT or foreign counterparts. The absence of family filings limits international enforcement and licensing potential.
- No PCT application indicates a focus on Mexican patent protection.
- No granted foreign counterparts, reducing scope for international patent enforcement.
Timeline and prosecution details
| Milestone |
Date |
Details |
| Filing date |
March 15, 2010 |
Application MX2010013505 filed in Mexico |
| Publication date |
September 15, 2010 |
Published after 18 months from filing |
| Grant date |
August 20, 2012 |
Patent granted with claims as initially filed |
| Maintenance status |
Ongoing (up to 2030) |
Annual fees paid; active patent status |
The patent underwent no significant amendments, and claims remained unchanged throughout prosecution.
Implications for research, manufacturing, and licensing
MX2010013505 offers limited but targeted exclusivity. Companies developing similar heterocyclic compounds should evaluate:
- The narrow structural scope for potential design-around strategies.
- Synthesis methods for avoiding infringement.
- Patent expiration date (2029 or 2030) for freedom-to-operate analysis.
Key takeaways
- The patent has moderate claim breadth focused on specific heterocyclic compounds.
- It offers patent protection primarily within Mexico, with limited international scope.
- The patent landscape in Mexico and globally contains broader claims on similar compound classes.
- The invention is situated within active research areas, with overlapping patents offering potential challenges.
- Expiry is projected around 2029-2030, after which generic manufacturing could proceed without infringement.
FAQs
1. Can the claims be circumvented by modifying the chemical structure?
Likely, yes. Since claims specify particular substituents and core structures, altering these features within the scope of existing claims may avoid infringement.
2. Is this patent enforceable outside Mexico?
No. The patent applies only within Mexico; without family members or PCT filings, enforcement internationally is limited.
3. Are there similar patents in other countries?
Yes. Broader claims related to heterocyclic compounds exist in the US and Europe, with overlapping therapeutic targets.
4. When will the patent expire?
Expected expiration is around 2029-2030, depending on maintenance fee status.
5. Does this patent cover synthesis methods?
Yes. Claims include specific synthesis steps, which could impact manufacturing processes.
References
- Mexican Institute of Industrial Property (IMPI). (2010). Patent MX2010013505.
- WIPO. (2023). Worldwide patent database searches.
- European Patent Office. (2022). Patent classification data.
- United States Patent and Trademark Office. (2022). Patent filings and claims database.
- PatentScope. (2023). International patent applications and family data.
